ACHE and Alzheimer disease: This fact has not prevented research on tetrahydroacridine derivatives, such as cylopentaquinoline, partly because these structures demonstrate good activity towards AChE and partly because they have lower molecular masses, which are associated with favourable pharmacokinetics in AD therapy.